Cognitive dysfunction associated with chemotherapy for breast cancer

Future Neurology

Volumn 2, Issue 3, 2007, Pages 271-277

  Silverman, Daniel H S ^a   Castellon, Steven A ^a   Ganz, Patricia A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemobrain; Cognitive dysfunction; Cognitive impairment; Magnetic resonance imaging; Positron emission tomography

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; DOXORUBICIN; TAMOXIFEN;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; COGNITIVE DEFECT; DISEASE ASSOCIATION; ELECTROENCEPHALOGRAM; HUMAN; INCIDENCE; INFORMED CONSENT; MONOTHERAPY; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; PATIENT CARE; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; RISK REDUCTION; SYMPTOMATOLOGY;

EID: 34249338383     PISSN: 14796708     EISSN: None     Source Type: Journal    
DOI: 10.2217/14796708.2.3.271     Document Type: Article

References (23)

1. American Cancer Society: Cancer Facts & Figures 2007. American Cancer Society, USA (2007).
2. Ahles TA, Saykin AJ: Cognitive effects of standard-dose chemotherapy in patients with cancer. Cancer Invest. 19, 821-820 (2001).
3. Meyers CA: Neurocognitive dysfunction in cancer patients. Oncology (Willisten Park) 14, 75-79 (2000).
4. Ahles TA, Saykin AJ, Furstenberg CT et al.: Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J. Clin. Oncol. 20, 485-493 (2002).
5. Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF: Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J. Clin. Oncol. 18, 2695-2701 (2000).
6. Castellon SA, Ganz P, Bower JE, Petersen L, Abraham L, Greendale GA: Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J. Clin. Exp. Neuropsychol. 26, 955-969 (2004).
7. Tchen N, Juffs HG, Downie FP: Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J. Clin. Oncol. 21, 4175-4183 (2003).
8. van Dam FS, Schagen SB, Muller MJ et al.: Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J. Natl Cancer Inst. 90, 210-218 (1998).
9. Bender C, Sereika S, Berga S et al.: Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology 15, 422-430 (2006).
10. Hurria A, Rosen C, Hudis C et al.: Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. J. Am. Geriatr. Soc. 54, 925-931 (2006).
11. Jenkins V, Shilling V, Deutsch G et al.: A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br. J. Cancer. 94, 828-834 (2006).
12. Fan HG, Houede-Tchen N, Yi QLG et al.: Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1-and 2-year follow-up of a prospective controlled study. J. Clin. Oncol. 23, 8025-8032 (2005).
13. Wefel JS, Lenzi R, Theriault RL, Meyers CA: The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100, 2292-2299 (2004).
14. Schagen SB, Muller MJ, Boogerd W, Mellenbergh GJ, van Dam FS: Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J. Natl Cancer Inst. 98, 1742-1745 (2006).
15. Silverman DH, Small GW, Chang CY et al.: Positron emission tomography in evaluation of dementia. Regional brain metabolism and long-term outcome. JAMA 286(17), 2120-2127 (2001).
16. Jenkins V, Shilling V, Fallowfield L, Howell A, Hutton S: Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology 13, 61-66 (2004).
17. Silverman DHS, Dy CJ, Castellon SA et al.: Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res. Treat. doi10.1007/s10549-006-9380-z (2007) (Epub ahead of print).
18. Eberling JL, Wu C, Tong-Turnbeaugh R, Jagust WJ: Estrogen and tamoxifen-associated effects on brain structure and function. NeuroImage 21, 364-371 (2004).
19. Inagaki M, Yoshikawa E, Matsuoka Y et al.: Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 109, 146-156 (2007).
20. Castellon SA, Silverman DH, Ganz PA: Breast cancer treatment and cognitive functioning: current status and future challenges in assessment. Breast Cancer Res. Treat. 92, 199-206 (2005).
21. Silverman DH, Siu E, Castellon SA et al.: Parietal and temporal cortical activity associated with cognitive symptoms and depression in chemotherapy treated breast cancer survivors 5 to 10 years after end of chemotherapy. J. Nucl. Med. 48 (Published abstract) (2007).
22. Silverman DHS, Melega WP: Molecular imaging of biological processes with PET: evaluating biologic bases of cerebral function. In: PET: Molecular Imaging and its Biological Applications. Phelps ME (Ed.), Springer-Verlag, NY, USA 509-583 (2004).
23. Tran A, Pio BS, Khatibi B, Czernin J, Phelps ME, Silverman DHS: 18F-FDG PET for staging breast cancer in patients with inner-quadrant versus outer-quadrant tumors: comparison with long-term clinical outcome. J. Nucl. Med. 46, 1455-1459 (2005).